baxdela™ (delafloxacin) TableTs and injecTion for acUTe bacTerial skin and skin sTrUcTUre infecTion June 19, 2017 The US Food and Drug Administration (FDA) has approved Baxdela ™ (Delafloxacin) for the treatment of acute bacterial skin and skin structure infection (ABSSSI). The drug is a quinolone but has a different size, shape, and charge profile, making it more effective than other member of the same class, especially against Gram-positive organisms. A study of 660 patients comparing intravenous (IV) delafloxacin 300 mg with IV vancomycin 15 mg/kg plus aztreonam 2 g given twice daily in cases of adults with acute bacterial skin infections found delafloxacin to be comparable. [1] Delafloxacin can be used for the treatment of ABSSSI caused by the Gram-positive and Gram-negative bacteria. Delafloxacin offers the potential to treat Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus and Gram-negative pathogens without the need for combination therapy. The US FDA has approved ustekinumab (Stelara™, Jansen Biotech) for the treatment of patients aged 12 years and older with moderate-to-severe psoriasis. Patients who were initially candidates for phototherapy or systemic therapy are indications for ustekinumab. This interleukin 12/23 inhibitor was approved in 2009 for the treatment of adults with moderate-to-severe plaque psoriasis. The safety profile was similar to adults. Ustekinumab is administered subcutaneously at weeks 0, 4, and every 12 weeks thereafter.
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The recombinant herpes zoster vaccine (Adjuvanted) (Shingrix) has been approved in Canada for the prevention of herpes zoster in people aged 50 years and older. The vaccine contains a combination of an antigen, glycoprotein E, and an adjuvant system, ASO1B. This leads to long-lasting immune response in the elderly. Shingrix is given intramuscularly in the form of two doses at 2 to 6-month interval. The most common adverse effects were pain, redness, and swelling at the site of injection. The sale of prescription-strength steroid creams without prescription has become a menace in India. However, the menace has even spread to first-world countries now like the US. Potent steroid combination creams are now available on online retail websites such as Amazon.com and ebay.com. These products are sold as skin care products for as high as $25 a tube. The US FDA has approved Tremfya™ (guselkumab) for the treatment of adults with moderate-to-severe plaque psoriasis. Tremfya™ is an IgG1 human monoclonal antibody, which blocks interleukin 23 receptor. This prevents the release of pro-inflammatory cytokines. Recommended doses include 100 mg subcutaneous injections at weeks 0, 4, and every 8 weeks thereafter. Adverse effects may include, but not limited to, the following: upper respiratory tract infections, headache, injection-site reactions, diarrhea, gastroenteritis, tinea, and herpes infections.
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